Malaria chemoprophylaxis: when should we use it and what are the options?
- 1 February 2004
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 2 (1), 119-132
- https://doi.org/10.1586/14787210.2.1.119
Abstract
Malaria chemoprophylaxis concerns prescribing healthy individuals medication for an infection they have an unknown chance of getting. Sensible use of malaria chemoprophylaxis is a balance between the risk of infection and death, and the risk of side effects. The risk of infection can be broken down into the risk of being bitten by a malaria-infected mosquito and the risk of the malaria parasites being resistant to the drug used for prophylaxis. Our knowledge of these parameters is patchy. The risk of infection is not uniform at a given location and the standard of living will greatly influence risk. It is suggested that chemoprophylaxis should not be recommended in areas with less than ten reported cases of P. falciparum malaria per 1000 inhabitants per year. The resistance pattern is known to a certain extent but, for instance, diverging opinion of how much resistance to chloroquine there is in West Africa illustrates the lack of data. There is much debate on rare adverse events, which usually escape Phase III studies prior to registration and are only picked up by passive, postmarketing surveillance. The lessons over the past 20 years with the introduction of amodiaquine, pyrimethamine/dapsone (Maloprim, GlaxoSmithKline) and pyrimethamine/sulfadoxine (Fansidar, Roche), which were all withdrawn for prophylaxis after a few years, show how sensitive drugs for chemoprophylaxis are to side effects. Three levels of chemoprophylaxis are used: chloroquine in areas with sensitive P. falciparum, chloroquine plus proguanil in areas with low level chloroquine resistance, and atovaquone/proguanil (Malarone, GlaxoSmithKline), doxycycline or mefloquine (Lariam, Roche) in areas with extensive resistance against chloroquine and proguanil. Primaquine and the primaquone analog tafenoquine may be future alternatives but otherwise there are few new drugs for chemoprophylaxis on the horizon.Keywords
This publication has 71 references indexed in Scilit:
- A Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Ranging Trial of Tafenoquine for Weekly Prophylaxis againstPlasmodium falciparumClinical Infectious Diseases, 2003
- MEFLOQUINE-INDUCED PSYCHOSISThe Pediatric Infectious Disease Journal, 2000
- Primaquine as Prophylaxis for Malaria for Nonimmune Travelers: A Comparison with Mefloquine and DoxycyclineClinical Infectious Diseases, 1999
- Retrospective Evaluation of Exposure to P. falciparum using Antibodies to Circumsporozoite Protein and to Cultured P. Falciparum AntigensScandinavian Journal of Infectious Diseases, 1999
- Hyperpigmented dermal macules in children following the administration of Maloprim® for malaria chemoprophylaxisTransactions of the Royal Society of Tropical Medicine and Hygiene, 1997
- Atovaquone plus proguanil is an effective treatment for Plasmodium ovale and P. malariae malariaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1996
- The risk of malaria in travellers to ThailandTransactions of the Royal Society of Tropical Medicine and Hygiene, 1996
- Long-term malaria prophylaxis with weekly mefloquineThe Lancet, 1993
- Neurologic Reactions after a Therapeutic Dose of MefloquineNew England Journal of Medicine, 1989
- Fansidar-Induced Stevens-Johnson SyndromeNew England Journal of Medicine, 1982